| Year |
Citation |
Score |
| 2021 |
Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, et al. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. PMID 33654205 DOI: 10.1038/s41375-021-01181-w |
0.314 |
|
| 2019 |
Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, et al. Targetable genetic alterations of () drive immunoglobulin expression in diffuse large B cell lymphoma. Science Translational Medicine. 11. PMID 31217338 DOI: 10.1126/Scitranslmed.Aav5599 |
0.422 |
|
| 2016 |
Sun B, Fiskus W, Zhang L, Raina K, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Saenz DT, Mill CP, Wang M, Crews C, Bhalla KN. Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells Blood. 128: 1058-1058. DOI: 10.1182/Blood.V128.22.1058.1058 |
0.313 |
|
| 2015 |
Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. PMID 26254443 DOI: 10.1182/Blood-2015-04-639542 |
0.326 |
|
| 2015 |
Sun B, Fiskus W, Saenz DT, Krieger S, Zhang L, Parmar S, Wang M, Bhalla KN. BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells Blood. 126: 3704-3704. DOI: 10.1182/Blood.V126.23.3704.3704 |
0.323 |
|
| 2014 |
Sun B, Fiskus W, Shah B, Qi J, Devaraj SGT, Iyer SP, Sharma S, Bradner J, Zu Y, Bhalla KN. Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells Blood. 124: 918-918. DOI: 10.1182/Blood.V124.21.918.918 |
0.322 |
|
| 2013 |
Bhalla KN, Fiskus W, Peth K. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human AML. Journal of Clinical Oncology. 31: 11107-11107. DOI: 10.1200/Jco.2013.31.15_Suppl.11107 |
0.304 |
|
| 2010 |
Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4742-54. PMID 20647473 DOI: 10.1158/1078-0432.Ccr-10-0529 |
0.302 |
|
| 2006 |
Herger B, Fiskus W, Rao R, Bhalla K. Targeting Mutant Nucleophosmin (NPM)1: A Promising Approach To Induce Growth Inhibition and Differentiation in Human AML. Blood. 108: 1905-1905. DOI: 10.1182/Blood.V108.11.1905.1905 |
0.315 |
|
| 2003 |
Fiskus W, Padmalayam I, Kelly T, Guibao C, Baumstark BR. Identification and characterization of the DdlB, FtsQ and FtsA genes upstream of FtsZ in Bartonella bacilliformis and Bartonella henselae. Dna and Cell Biology. 22: 743-52. PMID 14659047 DOI: 10.1089/104454903770946728 |
0.544 |
|
| 2003 |
Padmalayam I, Fiskus W, Massung RF, Baumstark BR. Molecular cloning and analysis of a region of the Bartonella bacilliformis genome encoding NlpD, L-isoaspartyl methyltransferase and YajC homologs. Dna and Cell Biology. 22: 347-53. PMID 12941162 DOI: 10.1089/104454903322216699 |
0.508 |
|
| Show low-probability matches. |